Upfront Briefing
BioMarin's VOXZOGO hit Phase 3 in hypochondroplasia (+2.33 cm/yr AGV vs placebo) — a clean lifecycle-extension play onto an already-launched asset, with filings due in H2 2026.
Lilly bought Engage Bio for up to $202M to add a non-viral DNA delivery platform — its 7th acquisition this year — and cAMPfield's $180M Series A co-led by Novo Holdings and RA Capital underscored that scaled I&I stories still clear at premium pricing.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,433.0 |
1.1% |
8.4% |
| Nasdaq 100 |
29,297.7 |
1.7% |
16.2% |
| Russell 2000 |
2,817.4 |
2.6% |
12.3% |
| Healthcare (XLV) |
147.1 |
(0.1%) |
(5.4%) |
| Biotech (XBI) |
131.7 |
3.9% |
8.4% |
| Nasdaq Biotech (NBI) |
5,860.9 |
2.5% |
2.7% |
| Clinical Trials (BBC) |
42.5 |
4.8% |
12.9% |
|
- Biotech beta led the tape as risk appetite returned: XBI +3.9% and BBC +4.8% sharply outperformed the S&P 500's +1.1%, with the small-cap Russell 2000 (+2.6%) showing the rotation was broader than just biotech.
- Defensive healthcare was the outlier — XLV finished flat at (0.1%) while clinical-risk and small-cap biotech caught a bid, a clean read-through that investors are paying for catalyst exposure rather than large-cap pharma at current rates.
- Market data: US close Wed 20-May-2026.
The Big 3
|
1
|
BioMarin's VOXZOGO hits Phase 3 in hypochondroplasia
|
- The Phase 3 CANOPY-HCH-3 study of VOXZOGO (vosoritide) in children with hypochondroplasia met its primary endpoint, with a +2.33 cm/yr improvement in annualized growth velocity vs placebo at Week 52 (p<0.0001), plus stat-sig gains in standing height, height Z-score and arm span.
- Why it matters: Hypochondroplasia is materially more prevalent than achondroplasia (VOXZOGO's existing label), so this is a meaningful TAM expansion on an already-launched asset rather than a new clinical bet. BioMarin plans global regulatory submissions in H2 2026 — investors get a relatively clean lifecycle-extension story and stronger franchise durability against future competitors.
- Source: PR
|
|
2
|
Lilly buys Engage Bio for up to $202M for non-viral DNA delivery
|
- Lilly is acquiring San Carlos-based Engage Biologics for up to $202M in cash (undisclosed upfront + milestone-weighted) for its preclinical Tethosome platform — LNP-delivered DNA payloads combined with an mRNA-encoded DNA-binding protein designed to improve nuclear localization, potency and redosability.
- Why it matters: Lilly's 7th acquisition of 2026, extending its GLP-1-funded build-out in genetic medicines after Kelonia ($3.2B), Ajax ($2.3B), Orna and Ventyx. Capital-light, milestone-loaded bolt-on for a platform-layer capability — Lilly is increasingly owning the modality stack rather than renting it via partnerships, which compounds platform optionality across its pipeline.
-
Source:
BioSpace
|
| 3 | cAMPfield Therapeutics raises $180M Series A for I&I |
- San Diego-based, Bill Gerhart-led cAMPfield raised a $180M Series A co-led by Novo Holdings and RA Capital, joined by seven other top-tier life sciences investors. Lead asset is HPP737, a PDE4 inhibitor in-licensed from vtv Therapeutics, targeting inflammatory and immunology indications (psoriasis, atopic dermatitis, COPD, IPF).
- Why it matters: An outsized Series A for a clinical-ready, in-licensed asset — venture is still pricing scaled I&I stories with credible management at premium multiples, even as public-market sentiment around the space remains selective. Read-through: peer rounds will likely reset higher and crossover appetite for I&I remains intact heading into 2H 2026 IPO windows.
-
Source:
Endpoints
|
Everything Else that broke
- GHO Capital and CBC Group to merge, creating $21B+ AUM dedicated healthcare investor — closes early 2027. — Endpoints
- Pfizer's 25vPnC (next-gen 25-valent pneumococcal) shows strong Phase 2 data in infants vs Prevnar 20; pivotal Phase 3 initiated. — BioSpace
- FDA warning letter targets Chinese GLP-1 supplier. — BioSpace
- Bristol Myers expands AI push with Anthropic deal, deploying Claude across 30,000+ employees. — BioPharma Dive
- Incyte and Genesis Therapeutics expand molecular AI collaboration for drug discovery. — PharmExec
- US taps San Diego biotech for Ebola treatment. — Fierce Biotech
- Selvita reports Q1 and starts strategic review. — PR
- Mabwell wins NMPA nod for more denosumab uses. — PR
- Novartis previews ASCO and EHA oncology data slate (65+ abstracts). — PR
- STAT reports concern over FDA turnover in rare disease. — STAT
- GLP-1s reshape pharma's ties with consumers. — Endpoints
- Endpoints says next big pharma company will be Chinese. — Endpoints
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Lilly acquires Engage Bio for $202M. — BioSpace
VC / Private Financings
- cAMPfield Therapeutics (San Diego; I&I): $180M Series A co-led by Novo Holdings and RA Capital, joined by seven other top-tier life sciences investors. Lead asset HPP737 (PDE4 inhibitor in-licensed from vtv Therapeutics) for psoriasis / atopic dermatitis / COPD / IPF. — Endpoints
IPOs / Follow-Ons
- Parabilis Medicines (formerly FogPharma) files S-1 to list on Nasdaq as PBLS; concurrent $75M private placement from Regeneron tied to its $2.3B Helicon platform deal. Use of proceeds: Phase 3 zolucatetide programme in desmoid tumours (74% ORR Phase 1). — BioPharma Dive
- Jupiter Neurosciences prices $2.0M registered direct offering. — PR
- Nanobiotix launches global follow-on offering. — PR
Academic Corner - Directed evolution of small RNA-stabilizing motifs that improve prime-editing efficiency. — Nature Biotech
- HPV vaccines, 20 years on. — Nature Medicine
- Pathogenic germline variations and cancer risks in pediatric patients referred for genetic testing. — Nature Medicine
- FDA approves first-in-class hypertension drug. — Nature RDD
- The Vaccine-Hesitant Moment. — NEJM
|
